NO944700L - Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene - Google Patents

Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene

Info

Publication number
NO944700L
NO944700L NO944700A NO944700A NO944700L NO 944700 L NO944700 L NO 944700L NO 944700 A NO944700 A NO 944700A NO 944700 A NO944700 A NO 944700A NO 944700 L NO944700 L NO 944700L
Authority
NO
Norway
Prior art keywords
substituted
aryl
lower alkyl
heteroaryl
heteroatoms
Prior art date
Application number
NO944700A
Other languages
English (en)
Other versions
NO944700D0 (no
Inventor
Dieter Binder
Josef Weinberger
Original Assignee
Chem Pharm Forsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT253093A external-priority patent/AT400437B/de
Priority claimed from AT253193A external-priority patent/AT400567B/de
Priority claimed from AT102694A external-priority patent/AT400568B/de
Application filed by Chem Pharm Forsch Gmbh filed Critical Chem Pharm Forsch Gmbh
Publication of NO944700D0 publication Critical patent/NO944700D0/no
Publication of NO944700L publication Critical patent/NO944700L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet nye tlenotlazln-derlvater med generell formel: hvori: o o," s- N M-Q-R \\ f OR, (D A betyr laverealkyl, perfluorert laverealkyl, laverealkyl - oksy, halogen, nltro, cyano eller en mono- eller polycykllsk 5-12-leddet, eventuelt delvis hydrert aryl- eller heteroaryl- rest med 1-4 heteroatomer som O, S og N, som eventuelt kan være substituert med laverealkyl, per fluor laverealkyl , aryl, heteroaryl, substituert aryl, substituert hetero- aryl, halogen, laverealkoksy, aryloksy, substituert aryloksy, heteroaryloksy , substituert heteroaryloksy og nltro, hvori de aktuelle substltuentene l substituert aryl, substituert heteroaryl, substituert aryloksy og substituert heteroaryloksy betyr halogen, laverealkyl, perfluorlaverealkyl , laverealkoksy og lignende; w D betyr en 2-pyridylrest eller en rest X^TY , hvorved X og Y uavhengig av hverandre betyr CH, NR6, O eller S, hvor R6 betyr hydrogen eller laverealkyl, M betyr en enkeltbinding, en rettkjedet eller forgrenet hydrokarbonkjede med 1-12 karbonatomer i kjeden, hvorved denne kjeden kan inneholde en eller flere dobbelt- og/eller trippelbindinger og/eller et eller flere hetero- atomer som O, S og N, en 5-12-leddet mono- eller polycykllsk, eventuelt delvis hydrert aryl- eller heteroaryl- rest med 1-4 heteroatomer som O, S og N, som kan være substituert med halogen, laverealkyl eller laverealkoksy; O betyr en enkeltbinding eller et heteroatom som O, S og N; R betyr hydrogen, en 5-12-leddet mono- eller polycykllsk aryl- eller heteroaryl rest med 1-4 heteroatomer sera O, S og N, som eventuelt kan være delvis hydrert, eller også kan være substituert en eller flere ganger med halogen, laverealkyl eller laverealkoksy; R, O l ^^ og R! betyr hydrogen eller ¿ nvorl R2 betyr laverealkyl og #3 betyr laverealkyl, aryl eller -OR4, hvor R4 betyr laverealkyl, cykloalkyl med 4-8 karbonatomer eller aryl; samt deres farmasøytisk anvendbare salter. Det er videre beskrevet fremgangsmåter for fremstilling av forbin- delsene samt deres anvendelse ved fremstilling av legemidler.
NO944700A 1993-12-14 1994-12-06 Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene NO944700L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT253093A AT400437B (de) 1993-12-14 1993-12-14 Neue n-heterocyclische thienothiazincarboxamide, verfahren zu ihrer herstellung und ihre verwendung
AT253193A AT400567B (de) 1993-12-14 1993-12-14 Neue arylsubstituierte thienothiazinderivate, verfahren zu ihrer herstellung und ihre verwendung
AT102694A AT400568B (de) 1994-05-18 1994-05-18 Neue n-heterocyclische thienothiazincarboxamide, verfahren zu ihrer herstellung und ihre verwendung

Publications (2)

Publication Number Publication Date
NO944700D0 NO944700D0 (no) 1994-12-06
NO944700L true NO944700L (no) 1995-06-15

Family

ID=27146994

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944700A NO944700L (no) 1993-12-14 1994-12-06 Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene

Country Status (6)

Country Link
US (1) US5679678A (no)
EP (1) EP0658559A1 (no)
JP (1) JPH07267964A (no)
CN (1) CN1109059A (no)
CA (1) CA2137976A1 (no)
NO (1) NO944700L (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
BR9916583A (pt) * 1998-12-25 2001-09-25 Shionogi & Co Derivados heteroaromáticos tendo uma atividade inibitória contra integrase de hiv
WO2001005780A1 (en) * 1999-07-16 2001-01-25 Sankyo Company, Limited Coumarone analogues
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
EP2363396A1 (en) 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
CN1171892C (zh) 2001-06-25 2004-10-20 李晶 具有抗炎镇痛活性的噻吩并噻嗪化合物及其制备方法和用途
EP1474141A1 (en) * 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd 5-ht2b receptor antagonists
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
GB0203412D0 (en) * 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
AT413944B (de) * 2003-05-27 2006-07-15 Binder Eva Dkfm Verwendung von oxicam-verbindungen
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
SG176488A1 (en) 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PL2797416T3 (pl) * 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
US9499533B2 (en) * 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6426694B2 (ja) * 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN106632403B (zh) * 2017-01-23 2018-09-11 牡丹江医学院 一种手术用止痛消炎药及其制备方法
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
PT3880654T (pt) 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN111646987B (zh) * 2020-06-05 2022-06-24 湖南师范大学 一种5-氨基噻唑类非甾体抗炎化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47877A (en) * 1974-08-26 1978-10-31 Sparamedica Ag Thienothiazine carboxamide derivatives,their manufacture and pharmaceutical compositions containing them
CH619236A5 (en) * 1975-08-14 1980-09-15 Hoffmann La Roche Process for the preparation of thienothiazine derivatives
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
EP0103142B1 (de) * 1982-09-09 1987-04-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Thieno(2,3-e)-1,2-thiazin-Derivate
IL87951A (en) * 1987-10-29 1992-03-29 Chem Pharm Forsch Gmbh Carbonic acid esters of 6-chloro-4-(1-hydroxyethoxy)-2-methyl-n-(2-pyridyl)-2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide,their preparation and pharmaceutical compositions containing them
AT399880B (de) * 1992-07-03 1995-08-25 Chem Pharm Forsch Gmbh Neue thienothiazinderivate, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
US5679678A (en) 1997-10-21
JPH07267964A (ja) 1995-10-17
NO944700D0 (no) 1994-12-06
CN1109059A (zh) 1995-09-27
CA2137976A1 (en) 1995-06-15
EP0658559A1 (de) 1995-06-21

Similar Documents

Publication Publication Date Title
DK0687253T3 (da) Hidtil ukendte 4-aminopyridiner, fremgangsmåde til deres fremstilling samt lægemidler indeholdende disse forbindelser
US3488423A (en) Process for producing anti-inflammatory effects and compositions
DE68906552D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
ES483767A1 (es) Procedimiento para producir n-arilsulfonil-l-argininamidas
IL129724A0 (en) Crystals of benzimidazole derivatives and their production
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
UA8022A1 (uk) Спосіб одержання похідних бензімідазолу у вигляді суміші ізомерів або індивідуальних ізомерів у вільному вигляді або у вигляді їх фізіологічно прийнятих солей
NO913923L (no) 17beta-substituerte-4-aza-5alfa-androstan-3-on-derivater ogfremgangsmaate ved fremstilling av disse
CA2161542A1 (en) Novel 5-Pyrrolyl-2-Pyridylmethylsulfinyl Benzimidazole Derivatives
DE68916699D1 (de) Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
NO970293L (no) Substituerte camptothecinderivater og fremgangsmåte for deres fremstilling
SE7501365L (no)
UA8017A1 (uk) Спосіб отримання похідних хінолінкарбонової кислоти
AU2186288A (en) Novel amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same
PT72574B (en) Process for the preparation of 1,1-diphenyl-2-(1,2,4-triazol-1--yl)ethanols and of pharmaceutical compositions containing them
ECSP941050A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene
NO944680L (no) Nye tienotiazinerivater, en fremgangsmåte til fremstilling derav samt deres anvendelse
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
NO932129L (no) Fremgangsmaate for fremstilling og anvendelse av nye tienotiazinderivater
NO920619L (no) Oxazinobenzazolforbindelser
ATE168371T1 (de) 5-amino-5,6,7,8-tetrahydrochinoline und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DK0432841T3 (da) Spiro-indolin-oxazin-forbindelser med fotokromatiske og fotosensibiliserende egenskaber samt fremgangsmåde til deres fremstilling
HU903511D0 (en) Process for producing aminoketone derivatives and pharmaceutical preparatives containing these compounds
GB898409A (en) Process for the manufacture of 2-amino-ú=-triazolo[2,3-c]pyrimidines